- Home
- CRDF vs ACRS Comparison
CRDF vs ACRS Comparison
Compare CRDF & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- ACRS
- Stock Information
- Founded
- CRDF 1999
- ACRS 2012
- Country
- CRDF United States
- ACRS United States
- Employees
- CRDF N/A
- ACRS N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- CRDF Health Care
- ACRS Health Care
- Exchange
- CRDF Nasdaq
- ACRS Nasdaq
- Market Cap
- CRDF 133.5M
- ACRS 132.0M
- IPO Year
- CRDF N/A
- ACRS 2015
- Fundamental
- Price
- CRDF $4.96
- ACRS $3.00
- Analyst Decision
- CRDF Strong Buy
- ACRS Strong Buy
- Analyst Count
- CRDF 3
- ACRS 5
- Target Price
- CRDF $10.33
- ACRS $8.75
- AVG Volume (30 Days)
- CRDF 3.9M
- ACRS 4.2M
- Earning Date
- CRDF 11-07-2024
- ACRS 11-06-2024
- Dividend Yield
- CRDF N/A
- ACRS N/A
- EPS Growth
- CRDF N/A
- ACRS N/A
- EPS
- CRDF N/A
- ACRS N/A
- Revenue
- CRDF $688,000.00
- ACRS $27,079,000.00
- Revenue This Year
- CRDF $23.78
- ACRS N/A
- Revenue Next Year
- CRDF N/A
- ACRS N/A
- P/E Ratio
- CRDF N/A
- ACRS N/A
- Revenue Growth
- CRDF 49.57
- ACRS 26.35
- 52 Week Low
- CRDF $1.30
- ACRS $0.80
- 52 Week High
- CRDF $6.42
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- CRDF 72.82
- ACRS 46.47
- Support Level
- CRDF $3.06
- ACRS $2.91
- Resistance Level
- CRDF $5.64
- ACRS $3.29
- Average True Range (ATR)
- CRDF 0.45
- ACRS 0.29
- MACD
- CRDF 0.29
- ACRS -0.17
- Stochastic Oscillator
- CRDF 84.32
- ACRS 11.21
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.